BioWorld

Feb. 22, 2008

Genmab Pays $240M for PDL's Antibody Manufacturing Facility

Strengthening its position as a major antibody player, Genmab A/S said it is securing its own manufacturing capability in a deal to acquire troubled PDL BioPharma Inc.'s Brooklyn, Minn., facility for $240 million. (BioWorld Today) Read More

Affomix Closes $7M Series A for Automatic Antibody Effort

Glutamate Newest Transmitter Found to Influence Platelets

NewCo News: With Fresh Eggs, Stemagen Inc. Manages Fresh Cloning Start

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 23, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 23, 2026.

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...